Stem Cell Adaptibility in Parkinson's Disease Clinical trials have provided encouraging evidence that grafts of fetal dopamine neurons are an effective therapeutic approach toward counteracting the symptoms of Parkinson's disease (PD). Modest therapeutic benefits are observed in grafted patients despite clinical and experimental evidence that survival of grafted cells is low and graft reinnervation is incomplete. Recently it was demonstrated embryonic stem ceils (ESC) could be converted to dopamine neurons in culture and, when implanted into animals with experimental Parkinson's disease, produced a degree of functional recovery similar to implants of fetal dopamine neurons. Because dopamine neurons derived from ESC are generated in cultures by manipulating various growth factors, it still remains to be determine whether or not ESC-derived dopamine neurons have a similar phenotype as normal developing dopaminergic neurons. Moreover, the dynamic microenvironment of the brain, particularly the neurotrophic environment, may alter the survival, function, and even the fate of transplanted ESC. The objective of the initial studies will determine whether or not ESC-derived dopamine neurons retain various cellular markers that are critical to the survival and maintenance of developing and mature dopamine neurons. In particular, studies will focus on the identification of neurotrophic factors and neurotrophic factor receptors on ESC-derived dopamine neurons that are typically associated with normal dopamine neurons. We will then identify and measure various growth factors within the host brain that may influence the fate of transplanted ESC, and assess how these factors change following a degenerative lesion of the nigrostriatal and/or during aging. Studies will be designed to vary the neurotrophic environment of the host brain in order to determine the adaptability of implanted ESC; conditions will be varied using various lesion models and gene therapy techniques to alter the expression of neurotrophic factors. The variable of host age on ESC-derived dopamine neuron adaptability will be studied.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS050311-02
Application #
6986045
Study Section
Clinical Neuroplasticity and Neurotransmitters Study Section (CNNT)
Program Officer
Murphy, Diane
Project Start
2004-12-01
Project End
2009-11-30
Budget Start
2005-12-01
Budget End
2006-11-30
Support Year
2
Fiscal Year
2006
Total Cost
$314,479
Indirect Cost
Name
University of Kentucky
Department
Surgery
Type
Schools of Medicine
DUNS #
939017877
City
Lexington
State
KY
Country
United States
Zip Code
40506
Zhang, C; Jin, Y; Ziemba, K S et al. (2013) Long distance directional growth of dopaminergic axons along pathways of netrin-1 and GDNF. Exp Neurol 250:156-64
Cass, Wayne A; Peters, Laura E; Fletcher, Anita M et al. (2012) Evoked dopamine overflow is augmented in the striatum of calcitriol treated rats. Neurochem Int 60:186-91
Yurek, David M; Fletcher, Anita M; McShane, Matthew et al. (2011) DNA nanoparticles: detection of long-term transgene activity in brain using bioluminescence imaging. Mol Imaging 10:327-39
Fletcher, A M; Kowalczyk, T H; Padegimas, L et al. (2011) Transgene expression in the striatum following intracerebral injections of DNA nanoparticles encoding for human glial cell line-derived neurotrophic factor. Neuroscience 194:220-6
Yurek, David M; Fletcher, Anita M; Peters, Laura E et al. (2010) Strain difference in the up-regulation of FGF-2 protein following a neurotoxic lesion of the nigrostriatal pathway. Neurochem Res 35:531-9
Yurek, David M; Flectcher, Anita M; Kowalczyk, Tomasz H et al. (2009) Compacted DNA nanoparticle gene transfer of GDNF to the rat striatum enhances the survival of grafted fetal dopamine neurons. Cell Transplant 18:1183-96
Yurek, David M; Fletcher, Anita M; Smith, George M et al. (2009) Long-term transgene expression in the central nervous system using DNA nanoparticles. Mol Ther 17:641-50